Rebound Hypercalcemia After Denosumab Cessation During Follow-up After Surgical Treatment for Parathyroid Carcinoma: Case Report and Literature Review

Overview

Journal Arch Endocrinol Metab

Specialty Endocrinology

Date 2024 Nov 12

PMID 39529981

Authors

Lisa Schmitt

Verena Theiler-Schwetz

Patrick Sadoghi

Christian Trummer

Stefan Pilz

Affiliations

Soon will be listed here.

Abstract

Denosumab is a potent antiresorptive medication, commonly used in the treatment of osteoporosis, as well as in a variety of other diseases. Potential adverse rebound effects after its cessation include a loss in bone mineral density and an increased risk of osteoporotic fractures. Hypercalcemia is a less frequently reported rebound phenomenon after denosumab discontinuation, that may pose a diagnostic challenge to physicians as a rare non-parathyroid hormone (PTH) dependent cause of hypercalcemia. In our case, a 47-year-old male presented with rebound hypercalcemia after denosumab cessation during follow-up after surgical treatment for parathyroid carcinoma. This non-PTH-dependent hypercalcemia resolved after re-initiation of denosumab. We performed a systematic literature review on rebound hypercalcemia after denosumab cessation and identified 52 individual patient cases. Children appear to be more prone to developing rebound hypercalcemia, which could be attributed to their higher baseline bone turnover, underlying conditions, or denosumab dosage regimens. In most cases, patients initially presented with acute and often severe symptoms of hypercalcemia that occur from 1.75 to 9 months after denosumab cessation (4 to 9 months in adults). Most effective treatment approaches to sufficiently decrease serum calcium levels were bisphosphonates or re-administration of denosumab. A watch and wait strategy may be sufficient in asymptomatic cases, which are less common and probably underdiagnosed. Subsequent antiresorptive treatment after denosumab cessation, which is a common practice in osteoporosis treatment, may reduce the risk of rebound hypercalcemia. As denosumab is a frequently used drug in patients with advanced malignant diseases and rebound hypercalcemia with low PTH levels may raise the suspicion for skeletal metastases, awareness of this rebound effect may be for particular relevance in such settings.

References

Meier M, Clerkx S, Winter E, Pereira A, van de Ven A, van de Sande M . Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study. J Bone Miner Res. 2021; 36(9):1729-1738. PMC: 8518724. DOI: 10.1002/jbmr.4380. View

Naidu A, Malmquist M, Denham C, Schow S . Management of central giant cell granuloma with subcutaneous denosumab therapy. J Oral Maxillofac Surg. 2014; 72(12):2469-84. DOI: 10.1016/j.joms.2014.06.456. View

Anastasilakis A, Makras P, Doulgeraki A, Polyzos S, Guarnieri V, Papapoulos S . Denosumab for the treatment of primary pediatric osteoporosis. Osteoporos Int. 2021; 32(11):2377-2381. DOI: 10.1007/s00198-021-06002-5. View

Roux S, Massicotte M, Huot Daneault A, Brazeau-Lamontagne L, Dufresne J . Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review. Bone. 2018; 120:482-486. DOI: 10.1016/j.bone.2018.12.012. View

Lamy O, Stoll D, Aubry-Rozier B, Rodriguez E . Stopping Denosumab. Curr Osteoporos Rep. 2019; 17(1):8-15. DOI: 10.1007/s11914-019-00502-4. View

Cummings S, San Martin J, McClung M, Siris E, Eastell R, Reid I . Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8):756-65. DOI: 10.1056/NEJMoa0809493. View

Grasemann C, Schundeln M, Hovel M, Schweiger B, Bergmann C, Herrmann R . Effects of RANK-ligand antibody (denosumab) treatment on bone turnover markers in a girl with juvenile Paget's disease. J Clin Endocrinol Metab. 2013; 98(8):3121-6. DOI: 10.1210/jc.2013-1143. View

Raborn L, Burke A, Ebb D, Collins M, Kaban L, Boyce A . Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects. Osteoporos Int. 2021; 32(9):1889-1893. DOI: 10.1007/s00198-021-05895-6. View

Durr H, Grahneis F, Baur-Melnyk A, Knosel T, Birkenmaier C, Jansson V . Aneurysmal bone cyst: results of an off label treatment with Denosumab. BMC Musculoskelet Disord. 2019; 20(1):456. PMC: 6802343. DOI: 10.1186/s12891-019-2855-y. View

10.

Bollerslev J, Schalin-Jantti C, Rejnmark L, Siggelkow H, Morreau H, Thakker R . MANAGEMENT OF ENDOCRINE DISEASE: Unmet therapeutic, educational and scientific needs in parathyroid disorders. Eur J Endocrinol. 2019; 181(3):P1-P19. PMC: 6598862. DOI: 10.1530/EJE-19-0316. View

11.

Choe M, Smith V, Okcu M, Wulff J, Gruner S, Huisman T . Treatment of central giant cell granuloma in children with denosumab. Pediatr Blood Cancer. 2020; 68(3):e28778. DOI: 10.1002/pbc.28778. View

12.

Raux S, Bouhamama A, Gaspar N, Brugieres L, Entz-Werle N, Mallet C . Denosumab for treating aneurysmal bone cysts in children. Orthop Traumatol Surg Res. 2019; 105(6):1181-1185. DOI: 10.1016/j.otsr.2019.04.028. View

13.

Solling A, Tsourdi E, Harslof T, Langdahl B . Denosumab Discontinuation. Curr Osteoporos Rep. 2022; 21(1):95-103. DOI: 10.1007/s11914-022-00771-6. View

14.

Ferriero K, Shah B, Yan Y, Khatri S, Caccamese J, Napoli J . Case Report: Safety and Efficacy of Denosumab in Four Children With Noonan Syndrome With Multiple Giant Cell Lesions of the Jaw. Front Pediatr. 2020; 8:515. PMC: 7530181. DOI: 10.3389/fped.2020.00515. View

15.

Wei C, Harari A . Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012; 13(1):11-23. DOI: 10.1007/s11864-011-0171-3. View

16.

Del Sindaco G, Berlanga P, Brugieres L, Thebault E, Mantovani G, Wicart P . Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report. Front Endocrinol (Lausanne). 2021; 12:698963. PMC: 8322664. DOI: 10.3389/fendo.2021.698963. View

17.

Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra N, Cardoso L . European Expert Consensus on Practical Management of Specific Aspects of Parathyroid Disorders in Adults and in Pregnancy: Recommendations of the ESE Educational Program of Parathyroid Disorders. Eur J Endocrinol. 2021; 186(2):R33-R63. PMC: 8789028. DOI: 10.1530/EJE-21-1044. View

18.

Ciancia S, Hogler W, Sakkers R, Appelman-Dijkstra N, Boot A, Sas T . Osteoporosis in children and adolescents: how to treat and monitor?. Eur J Pediatr. 2022; 182(2):501-511. DOI: 10.1007/s00431-022-04743-x. View

19.

Roser P, Leca B, Coelho C, Schulte K, Gilbert J, Drakou E . Diagnosis and management of parathyroid carcinoma: a state-of-the-art review. Endocr Relat Cancer. 2023; 30(4). DOI: 10.1530/ERC-22-0287. View

20.

Schulte K, Talat N . Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012; 8(10):612-22. DOI: 10.1038/nrendo.2012.102. View